Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Firms Told To Get Ready Now For New EU HTA Regulation

Executive Summary

Comparator selection and joint scientific consultation slots are among top concerns for companies operating in the EU as EUnetHTA 21 consortium preparations for new HTA regulations get going.

You may also be interested in...



European HTA Legislation Clears Final Hurdle

Risk of unpredictable system still real depending on how EU member states approach joint clinical assessments, warns industry.

New EU HTA Consortium Prepares To Launch

Two new groups have been formed in preparation for the application of the EU regulation on health technology assessment cooperation.

Proposals On EU-Wide Joint Clinical Assessments Fall Short, Warn German Industry Groups

The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel